(Alliance News) - Kanabo Group PLC on Tuesday said it launched two new medical cannabis extract formulas for inhalation.
The London-based cannabis-derived products distributor said the two products are designed to fill a gap in the market for premium products for patients with severe pain.
The new formulas will be available in versions suitable for day and evening use and will be branded as a Kanabo-Noidecs partnership with medical cannabis supplier LYPHE Group.
It will be used with the VapePod, containing high levels of tetrahydrocannabinol, low cannabidiol and cannabis naturally-derived terpenes.
Kanabo said the launch will broaden Kanabo's vape offering to the market, providing an additional step for the company to build a robust product offering to all eligible patients in the UK.
The new formulas will be available from next week to eligible patients via the Dispensary Green pharmacy.
"We are committed to improving patient access to prescribed medical cannabis through innovative technology and telemedicine services. Our new medical cannabis extract formulas for inhalation offer patients suffering from severe pain a premium option for managing their symptoms without the negative side effects of traditional cannabis flowers," said Kanabo Clinical Director Mehran Afshar.
Kanabo also said it is committed increasing patient access to prescribed medical cannabis in the UK by developing a new platform using its recently acquired UK subsidiary The GP Service Ltd.
"The company is pleased to announce that all the regulatory approvals have been obtained, and the testing stage of the platform has begun. Additional updates will be provided in due course," Kanabo said in a statement.
Shares in Kanabo were up 1.9% to 1.96 pence each in London on Tuesday afternoon.
By Greg Rosenvinge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
